Hyaluronan, CD44 and versican in epidermal keratinocyte tumours.
BACKGROUND
The high molecular weight polysaccharide hyaluronan is a major component of the extracellular matrix between the vital cells of human skin epidermis. The levels of hyaluronan, and those of the hyaluronan receptor CD44 and the hyaluronan binding proteoglycan versican, correlate with the aggressiveness of different human carcinomas of epithelial origin.


OBJECTIVE
To study skin keratinocyte tumours for the expression of hyaluronan, the hyaluronan receptor CD44 and the hyaluronan binding proteoglycan versican.


METHODS
Paraffin-embedded sections of 114 basal cell carcinomas (BCC), 31 in situ carcinomas (ISC) and 35 squamous cell carcinomas (SCC) were stained with a hyaluronan specific probe, biotinylated hyaluronan binding complex, and with monoclonal antibodies against CD44 and versican.


RESULTS
Compared with normal epidermis, ISC and well differentiated SCCs showed an enhanced hyaluronan signal on carcinoma cells while CD44 expression level resembled that of normal skin. Less differentiated SCCs showed reduced and irregular expression of both hyaluronan and CD44 on carcinoma cells. In BCCs, hyaluronan and CD44 signals were absent or very low on the surface of carcinoma cells. However, hyaluronan was frequently present on BCC cell nuclei, a feature completely absent in ISC, SCC and normal epidermis. An accumulation of hyaluronan in the connective tissue stroma around the tumour was more frequent in SCCs than BCCs. Versican staining was positive around hair follicles and dermal blood vessels of normal skin. Peritumoral versican signal was present in a part of the BCCs but not in other tumours.


CONCLUSIONS
The completely different hyaluronan and CD44 expression patterns in BCC and SCC probably reflect the different origins of the tumours, with BCC an undifferentiated keratinocyte and SCC a keratinocyte at an early stage in the differentiation pathway. The difference in hyaluronan and CD44 expression between these tumours may also contribute to the difference in their capacity to metastasize.
Karvinen
S
S
Department of Anatomy and Pathology, University of Kuopio and Kuopio University Hospital, Finland.
Kosma
V-M
VM
Tammi
M I
MI
Tammi
R
R
D002277:Carcinoma / Q000378:metabolism*; D002278:Carcinoma in Situ / Q000378:metabolism; D002280:Basal Cell Carcinoma / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D006820:Hyaluronic Acid / Q000378:metabolism*; D007124:Immunoenzyme Techniques; D015603:Keratinocytes / Q000378:metabolism; D037181:Lectins, C-Type; D009363:Neoplasm Proteins / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism*; D053675:Versicans
D011508:Chondroitin Sulfate Proteoglycans; D018960:Hyaluronan Receptors; D037181:Lectins, C-Type; D009363:Neoplasm Proteins; D011509:Proteoglycans; C508322:VCAN protein, human; D053675:Versicans; D006820:Hyaluronic Acid